Literature DB >> 33804570

Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions.

Katsuaki Ieguchi1,2, Takeshi Tomita3, Toshifumi Takao4, Tsutomu Omori1, Taishi Mishima1, Isao Shimizu5, Massimiliano Tognolini6, Alessio Lodola6, Takuya Tsunoda7, Shinichi Kobayashi8, Satoshi Wada2,7,8, Yoshiro Maru1.   

Abstract

Accumulating evidence indicates that an elevated ephrin-A1 expression is positively correlated with a worse prognosis in some cancers such as colon and liver cancer. The detailed mechanism of an elevated ephrin-A1 expression in a worse prognosis still remains to be fully elucidated. We previously reported that ADAM12-cleaved ephrin-A1 enhanced lung vascular permeability and thereby induced lung metastasis. However, it is still unclear whether or not cleaved forms of ephrin-A1 are derived from primary tumors and have biological activities. We identified the ADAM12-mediated cleavage site of ephrin-A1 by a Matrix-assisted laser desorption ionization mass spectrometry and checked levels of ephrin-A1 in the serum and the urine derived from the primary tumors by using a mouse model. We found elevated levels of tumor-derived ephrin-A1 in the serum and the urine in the tumor-bearing mice. Moreover, inhibition of ADAM-mediated cleavage of ephrin-A1 or antagonization of the EphA receptors resulted in a significant reduction of lung metastasis. The results suggest that tumor-derived ephrin-A1 is not only a potential biomarker to predict lung metastasis from the primary tumor highly expressing ephrin-A1 but also a therapeutic target of lung metastasis.

Entities:  

Keywords:  ADAM; Eph; MMP; biomarker; cancer; ephrin; metastasis; poor prognosis; urinalysis

Mesh:

Substances:

Year:  2021        PMID: 33804570      PMCID: PMC7957476          DOI: 10.3390/ijms22052480

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  36 in total

Review 1.  Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche.

Authors:  Maria Felice Brizzi; Guido Tarone; Paola Defilippi
Journal:  Curr Opin Cell Biol       Date:  2012-08-13       Impact factor: 8.382

2.  Automated interpretation of high-energy collision-induced dissociation spectra of singly protonated peptides by 'SeqMS', a software aid for de novo sequencing by tandem mass spectrometry.

Authors:  J Fernandez-de-Cossio; J Gonzalez; L Betancourt; V Besada; G Padron; Y Shimonishi; T Takao
Journal:  Rapid Commun Mass Spectrom       Date:  1998       Impact factor: 2.419

3.  Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.

Authors:  Yingdi Wang; Masanori Nakayama; Mara E Pitulescu; Tim S Schmidt; Magdalena L Bochenek; Akira Sakakibara; Susanne Adams; Alice Davy; Urban Deutsch; Urs Lüthi; Alcide Barberis; Laura E Benjamin; Taija Mäkinen; Catherine D Nobes; Ralf H Adams
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

4.  Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma.

Authors:  Hiroshi Wada; Hirofumi Yamamoto; Chiwan Kim; Mamoru Uemura; Hirofumi Akita; Yoshito Tomimaru; Naoki Hama; Koichi Kawamoto; Shogo Kobayashi; Hidetoshi Eguchi; Koji Umeshita; Yuichiro Doki; Masaki Mori; Hiroaki Nagano
Journal:  Int J Oncol       Date:  2014-06-24       Impact factor: 5.650

5.  Δ(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system.

Authors:  Riccardo Castelli; Massimiliano Tognolini; Federica Vacondio; Matteo Incerti; Daniele Pala; Donatella Callegari; Simona Bertoni; Carmine Giorgio; Iftiin Hassan-Mohamed; Ilaria Zanotti; Antonella Bugatti; Marco Rusnati; Claudio Festuccia; Silvia Rivara; Elisabetta Barocelli; Marco Mor; Alessio Lodola
Journal:  Eur J Med Chem       Date:  2015-08-29       Impact factor: 6.514

6.  EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility.

Authors:  Tohru Yamazaki; Junko Masuda; Tsutomu Omori; Ryosuke Usui; Hitomi Akiyama; Yoshiro Maru
Journal:  J Cell Sci       Date:  2009-01-15       Impact factor: 5.285

Review 7.  Gene-based aggregate SNP associations between candidate AD genes and cognitive decline.

Authors:  Jasmine Nettiksimmons; Gregory Tranah; Daniel S Evans; Jennifer S Yokoyama; Kristine Yaffe
Journal:  Age (Dordr)       Date:  2016-03-22

Review 8.  Aberrant glycosylation as biomarker for cancer: focus on CD43.

Authors:  Franca Maria Tuccillo; Annamaria de Laurentiis; Camillo Palmieri; Giuseppe Fiume; Patrizia Bonelli; Antonella Borrelli; Pierfrancesco Tassone; Iris Scala; Franco Maria Buonaguro; Ileana Quinto; Giuseppe Scala
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

Review 9.  The Diverse Contributions of Fucose Linkages in Cancer.

Authors:  Tyler S Keeley; Shengyu Yang; Eric Lau
Journal:  Cancers (Basel)       Date:  2019-08-24       Impact factor: 6.639

10.  Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.

Authors:  Antonio Barquilla; Ilaria Lamberto; Roberta Noberini; Susanne Heynen-Genel; Laurence M Brill; Elena B Pasquale
Journal:  Mol Biol Cell       Date:  2016-07-06       Impact factor: 4.138

View more
  4 in total

Review 1.  EFNA1 in gastrointestinal cancer: Expression, regulation and clinical significance.

Authors:  Ling-Yu Chu; Bin-Liang Huang; Xu-Chun Huang; Yu-Hui Peng; Jian-Jun Xie; Yi-Wei Xu
Journal:  World J Gastrointest Oncol       Date:  2022-05-15

Review 2.  Proteolytic Cleavage of Receptor Tyrosine Kinases.

Authors:  Hao Huang
Journal:  Biomolecules       Date:  2021-04-29

Review 3.  The EPH/Ephrin System in Colorectal Cancer.

Authors:  Stavros P Papadakos; Leonidas Petrogiannopoulos; Alexandros Pergaris; Stamatios Theocharis
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

4.  Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph-Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice.

Authors:  Francesca Ferlenghi; Carmine Giorgio; Matteo Incerti; Lorenzo Guidetti; Paola Chiodelli; Marco Rusnati; Massimiliano Tognolini; Federica Vacondio; Marco Mor; Alessio Lodola
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.